Stem cells aim to slow lung scarring in early trial
NCT ID NCT07359963
First seen Jan 24, 2026 · Last updated May 16, 2026 · Updated 15 times
Summary
This early-phase study tests a stem cell product called REGEND007 in 12 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing difficulty. Participants receive the stem cells through an IV and are monitored for 12 weeks to check safety and any changes in lung function. The goal is to see if this approach is safe and might help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Fourth Hospital of Zhejiang University School of Medicine
Yiwu, Zhejiang, 322000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.